Cargando…

Time to Recurrence as a Prognostic Factor in Parathyroid Carcinoma

BACKGROUND: Parathyroid carcinoma (PC) is a rare and challenging disease without clearly understood prognostic factors. Adequate management can improve outcomes. Characteristics of patients treated for PC over time and factors affecting prognosis were analyzed. METHODS: Retrospective cohort study in...

Descripción completa

Detalles Bibliográficos
Autores principales: Magnabosco, Felipe Ferraz, Brescia, Marilia D’Elboux Guimarães, Nascimento Júnior, Climério Pereira, Massoni Neto, Ledo Mazzei, Arap, Sergio Samir, de Castro Junior, Gilberto, Ledesma, Felipe Lourenço, Ferreira Alves, Venancio Avancini, Kowalski, Luiz Paulo, Martin, Regina Matsunaga, de Menezes Montenegro, Fabio Luiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274572/
https://www.ncbi.nlm.nih.gov/pubmed/37334212
http://dx.doi.org/10.1210/jendso/bvad067
Descripción
Sumario:BACKGROUND: Parathyroid carcinoma (PC) is a rare and challenging disease without clearly understood prognostic factors. Adequate management can improve outcomes. Characteristics of patients treated for PC over time and factors affecting prognosis were analyzed. METHODS: Retrospective cohort study including surgically treated patients for PC between 2000 and 2021. If malignancy was suspected, free-margin resection was performed. Demographic, clinical, laboratory, surgical, pathological, and follow-up characteristics were assessed. RESULTS: Seventeen patients were included. Mean tumor size was 32.5 mm, with 64.7% staged as pT1/pT2. None had lymph node involvement at admission, and 2 had distant metastases. Parathyroidectomy with ipsilateral thyroidectomy was performed in 82.2%. Mean postoperative calcium levels were different between patients who developed recurrence vs those who did not (P = .03). Six patients (40%) had no recurrence during follow-up, 2 (13.3%) only regional, 3 (20%) only distant, and 4 (26.6%) both regional and distant. At 5 and 10 years, 79% and 56% of patients were alive, respectively. Median disease-free survival was 70 months. Neither Tumor, Nodule, Metastasis system nor largest tumor dimension (P = .29 and P = .74, respectively) were predictive of death. En bloc resection was not superior to other surgical modalities (P = .97). Time between initial treatment and development of recurrence negatively impacted overall survival rate at 36 months (P = .01). CONCLUSION: Patients with PC can survive for decades and have indolent disease course. Free margins seem to be the most important factor in initial surgery. Recurrence was common (60%), but patients with disease recurrence within 36 months of initial surgery had a lower survival rate.